Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence
Krishna Sriram, Paul A. Insel
doi: https://doi.org/10.1101/2020.03.25.20043927
Krishna Sriram
*Departments of Pharmacology, University of California San Diego, La Jolla, California 92093, USA
Ph.D.Paul A. Insel
*Departments of Pharmacology, University of California San Diego, La Jolla, California 92093, USA
^Departments of Medicine, University of California San Diego, La Jolla, California 92093, USA
M.D.Data Availability
There are no underlying data to report, this is a review of data in the literature, cited where appropriate.
Posted April 20, 2020.
Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence
Krishna Sriram, Paul A. Insel
medRxiv 2020.03.25.20043927; doi: https://doi.org/10.1101/2020.03.25.20043927
Subject Area
Subject Areas
- Addiction Medicine (322)
- Allergy and Immunology (625)
- Anesthesia (162)
- Cardiovascular Medicine (2347)
- Dermatology (206)
- Emergency Medicine (377)
- Epidemiology (11726)
- Forensic Medicine (10)
- Gastroenterology (697)
- Genetic and Genomic Medicine (3701)
- Geriatric Medicine (347)
- Health Economics (632)
- Health Informatics (2379)
- Health Policy (928)
- Hematology (340)
- HIV/AIDS (773)
- Medical Education (364)
- Medical Ethics (104)
- Nephrology (396)
- Neurology (3462)
- Nursing (195)
- Nutrition (520)
- Oncology (1805)
- Ophthalmology (534)
- Orthopedics (218)
- Otolaryngology (286)
- Pain Medicine (231)
- Palliative Medicine (66)
- Pathology (445)
- Pediatrics (1024)
- Primary Care Research (416)
- Public and Global Health (6105)
- Radiology and Imaging (1264)
- Respiratory Medicine (822)
- Rheumatology (375)
- Sports Medicine (320)
- Surgery (397)
- Toxicology (50)
- Transplantation (171)
- Urology (145)